Emerging insights and future prospects for therapeutic application of siRNA targeting angiotensinogen in hypertension.

Further studies should assess safety, efficacy, and outcomes in larger, more broadly representative groups. An advantage of zilebesiran is the potential for bi-annual dosing, thereby reducing nonadherence and improving control rates. It may also reduce nighttime blood pressure due to 24 h tonic control. The provision of adherence assessment services will maximize the clinical value of zilebesiran.